Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03593200
Other study ID # APL2-202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date August 16, 2018
Est. completion date October 22, 2019

Study information

Verified date December 2020
Source Apellis Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date October 22, 2019
Est. primary completion date October 22, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At least 18 years old (inclusive) - Diagnosed with PNH (white blood cell (WBC) clone >10%) - Lactose dehydrogenase (LD) =2 times the upper limit of normal - Screening Ferritin = normal and Total Iron Binding Capacity (TIBC) < LLN based on central lab reference ranges. If a subject is receiving iron supplements at screening, the investigator must ensure that his/her dose has been stable for 8 weeks prior to enrolment and must be maintained throughout the study - Last transfusion within 12 months prior to screening - Platelet count of >30,000/mm3 at the screening visit - Absolute neutrophil count >500/ mm3 at the screening visit - Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study - Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study - Vaccination against Neisseria meningitides types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day 1 dosing, or within 14 days after starting treatment with pegcetacoplan. Unless documented evidence exists that subjects are non-responders to vaccination as evidenced by titers or display titer levels within acceptable local limits - Willing and able to give informed consent Exclusion Criteria: - Prior eculizumab (SolirisĀ®) treatment - Active bacterial infection - Hereditary complement deficiency - History of bone marrow transplantation - Concurrent severe aplastic anemia (SAA), defined as currently receiving immunosuppressive therapy for SAA including but not limited to cyclosporin A, tacrolimus, mycophenolate mofetil or anti-thymocyte globulin - Participation in any other investigational drug trial or exposure to another investigational agent, device or procedure within 30 days - Evidence of QTcF prolongation defined as >450 ms for males and >470 ms for females at screening - Breast-feeding women - History of meningococcal disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pegcetacoplan
Complement (C3) Inhibitor

Locations

Country Name City State
Bulgaria Acibadem City Clinic MHAT Tokuda EAD Sofia Sofia
Bulgaria Specialized Hospital for Active Treatment of Hematologic Diseases EAD, Sofia Sofia
Serbia Klinicki centar Srbije Belgrade

Sponsors (1)

Lead Sponsor Collaborator
Apellis Pharmaceuticals, Inc.

Countries where clinical trial is conducted

Bulgaria,  Serbia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity TEAEs were defined as adverse events (AE) that occurred after dosing on Day 1 and up to 30 days after the last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possible, probable, or definite. TEAEs were graded according to the Common Terminology Criteria for Adverse Events (v4.03) based on: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening, Grade 5: Death related to AE. From Day 1 to 30 days after the last dose (approximately 56 weeks)
Primary Mean Change From Baseline in Lactate Dehydrogenase (LDH) Level Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period. Baseline and Day 365
Primary Mean Change From Baseline in Haptoglobin Level Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period. Baseline and Day 365
Primary Mean Change From Baseline in Hemoglobin (Hb) Level Hematology assessments of Hb were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period. Baseline and Day 365
Secondary Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score The FACIT-Fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher quality of life (QoL). Baseline and Day 365
Secondary Mean Change From Baseline in Absolute Reticulocyte Count (ARC) Level Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period. Baseline and Day 365
Secondary Mean Change From Baseline in Total Bilirubin Level Serum chemistry assessments of total bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period. Baseline and Day 365
Secondary Mean Number of Red Blood Cell (RBC) Transfusions Per Month The number of on-study RBC transfusions was monitored throughout the treatment period. From Day 1 to Day 364
Secondary Mean Change From Baseline in Linear Analog Scale Assessment (LASA) Score for QoL The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL. Baseline and Day 365
Secondary Mean Serum Concentrations of Pegcetacoplan Serum concentrations of pegcetacoplan at Day 365 are presented. Day 365
Secondary Mean Area Under the Serum Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration at the End of the Study (AUCtotal) The AUCtotal of pegcetacoplan was estimated using a non-compartmental approach. Blood samples were collected predose and at least 2.5 hours post dose on Day 1 and predose on Days 2 up to Day 365.
Secondary Mean Maximum Observed Predose Serum Concentration During the Study (Ctrough,Max,Total) The Ctrough,max,total of pegcetacoplan was estimated using a non-compartmental approach. Blood samples were collected predose and at least 2.5 hours post dose on Day 1 and predose on Days 2 up to Day 365.
See also
  Status Clinical Trial Phase
Terminated NCT04725812 - Complement Regulation to Undo Systemic Harm in Preeclampsia Phase 2
Completed NCT02598583 - Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 1/Phase 2
Recruiting NCT05539248 - A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH Phase 1/Phase 2
Active, not recruiting NCT03460301 - Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH N/A
Completed NCT01412047 - Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study N/A
Completed NCT02605993 - Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT05095168 - Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects Phase 1
Terminated NCT04702568 - A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT05337683 - A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean PNH Patients
Active, not recruiting NCT03531255 - Pegcetacoplan Long Term Safety and Efficacy Extension Study Phase 3
Not yet recruiting NCT06449001 - Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis Phase 3
Completed NCT05884060 - Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
Available NCT05982938 - Danicopan Early Access Program